Skip to content
HowShorted

Immunic, Inc. short interest in 2018

In 2018, Immunic, Inc.'s disclosed short interest ran from 10.02% of shares outstanding on 12 Jan 2018 to 5.74% on 31 Dec 2018, a change of -4.28 percentage points. The year's high was 23.52% on 31 Aug 2018 and its low 5.74% on 31 Dec 2018, averaging 14.05% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 45.95 days on 31 Jul 2018. Full history: Immunic, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Immunic, Inc. in 2018

2018 in figures

Start of year
10.02% (12 Jan 2018)
End of year
5.74% (31 Dec 2018)
Change
-4.28 pp
High
23.52% (31 Aug 2018)
Low
5.74% (31 Dec 2018)
Average
14.05%
Highest days to cover
45.95 (31 Jul 2018)
SEC filings marked
8

Every report in 2018

Immunic, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201810.02%29.80
31 Jan 201810.95%23.69
15 Feb 201812.22%23.73
28 Feb 201812.82%35.98
15 Mar 201813.28%42.6710-K filed, results (8-K)
29 Mar 201813.83%24.84
13 Apr 201814.83%33.24
30 Apr 201815.01%40.10
15 May 201815.77%28.3410-Q filed, results (8-K)
31 May 201816.49%18.98
15 Jun 201818.02%28.33
29 Jun 201820.81%14.41
13 Jul 201820.53%26.73
31 Jul 201820.50%45.95
15 Aug 201821.88%25.0510-Q filed, results (8-K)
31 Aug 201823.52%26.08
14 Sep 201816.93%1.00
28 Sep 20187.73%1.00
15 Oct 201810.59%1.00
31 Oct 201810.59%1.00
15 Nov 20189.22%1.0010-Q filed, results (8-K)
30 Nov 20187.95%3.17
14 Dec 20187.98%3.14
31 Dec 20185.74%2.19

See also: Immunic, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.